Form 4: Medpace Holdings Director Acquires Stock Options

Cornelius P. McCarthy III, a director of Medpace Holdings, Inc., acquired stock options on May 17, 2024.

Summary

• On May 17, 2024, Cornelius P. McCarthy III, a director of Medpace Holdings, Inc., acquired 953 stock options.
• The options have an exercise price of $393.30.
• The options vest on the earlier of the day before the first annual meeting following the grant date or the first anniversary of the grant date, contingent upon continued service on the board.
• The options expire on May 17, 2031.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock option acquisition, which is neutral in sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the pharmaceutical and healthcare industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like ICON plc and IQVIA Holdings also utilize stock options as part of their compensation strategy to align executive interests with shareholder value.
• The vesting schedule and exercise price are generally determined based on company performance and industry benchmarks.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates